On the stock market since 2018, it operates in the world of health and science. It has 6,000 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 6% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 73% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $1.2B a year; the problem isn’t sales — it’s costs running above that number.
The average analyst price target is $47.21 — 423% above today’s price.
A loss of $118.4M against $1.2B in annual sales.
At the current pace of spending, the cash lasts about 2.2 years. After that, the company needs to find new money.
Over the last 12 months, executives reported 21 sells against just 1 buy. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, TCNNF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: TCNNF has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.